Medivation

Dendreon, Zogenix, and Ampio Pharmaceuticals Could Be Big Movers Today
Motley Fool
Mon, 10/28/13 - 09:33 am
Dendreon
Zogenix
Ampio Pharmaceuticals
prostate cancer
Medivation
Zytiga
Provenge
Zohydro ER
Ampion
Here's Why Medivation Jumped Higher This Week
Motley Fool
Sat, 10/26/13 - 11:26 am
Medivation
Xtandi
prostate cancer
Medivation, Astellas prostate cancer drug meets trial goals
Yahoo/Reuters
Tue, 10/22/13 - 08:07 am
Medivation
prostate cancer
Astellas
Enzalutamide
Top 15 Drug Launch Superstars
Fierce Pharma
Thu, 10/3/13 - 10:35 am
drug launches
Eylea
Regeneron
Bayer
Tecfidera
Biogen Idec
Kalydeco
Vertex Pharmaceuticals
Kadcyla
Roche
Genentech
Victoza
Novo Nordisk
Gilenya
Novartis
Zytiga
JNJ
Yervoy
Bristol-Myers Squibb
Stribild
Gilead Sciences Xtandi
Medivation
Astellas
Afinitor
Amgen
Prolia
Stelara
Kyprolis
Xarelto
ONYX Pharmaceuticals
Dendreon: Time To Prove Itself Or Perish
Seeking Alpha
Thu, 10/3/13 - 09:11 am
Dendreon
prostate cancer
JNJ
Provenge
Medivation
Can Xtandi Become the Go-To Prostate Drug?
Motley Fool
Sat, 09/21/13 - 10:29 am
Xtandi
prostate cancer
Medivation
Astellas
No Generic Zytiga Benefits Medivation
Minyanville
Fri, 09/13/13 - 09:15 am
generics
Medivation
Zytiga
Dendreon: Crushed By JNJ/Medivation Or By Own Management?
Seeking Alpha
Mon, 09/9/13 - 05:19 pm
JNJ
Medivation
Dendreon
Provenge
Xtandi
Zytiga
prostate cancer
Are Biotech M&A Premiums Already Built In? Valuations Do Matter
Seeking Alpha
Tue, 09/3/13 - 04:19 pm
biotech
M&A
ONYX Pharmaceuticals
Alexion
Biomarin
Incyte
Medivation
Pharmacyclics
Regeneron
Seattle Genetics
These biotech names are ripe for takeover: Cramer
CNBC
Wed, 08/28/13 - 09:50 am
M&A
Amgen
ONYX Pharmaceuticals
Medivation
Astellas
Seattle Genetics
Biotech Buyouts: Who's Next?
Motley Fool
Thu, 08/22/13 - 05:35 pm
M&A
ONYX Pharmaceuticals
Amgen
Seattle Genetics
Medivation
Incyte
Investors Ride Dendreon and 4 Other Earnings Rollercoaster Rides
Wall St. Cheat Sheet
Mon, 08/12/13 - 09:21 am
earnings
Dendreon
Medivation
ONYX Pharmaceuticals
Impax Laboratories
Medivation Earnings: Everything You Must Know Now
Wall St. Cheat Sheet
Thu, 08/8/13 - 06:52 pm
earnings
Medivation
Zacks Industry Outlook Highlights: Johnson & Johnson, Forest Labs, Biogen, Amgen and Medivation
Yahoo/Zacks
Wed, 07/31/13 - 09:17 am
JNJ
Forest Labs
Biogen Idec
Amgen
Medivation
Breakthrough Prostate Cancer Treatment May Propel Medivation Into The Black
Forbes
Mon, 07/29/13 - 12:14 pm
prostate cancer
Medivation
Xtandi
The Best- And Worst-Performing Biotech Stocks, June 28 to July 5
Forbes
Mon, 07/8/13 - 11:02 am
biotech
ONYX Pharmaceuticals
Celldex
Novavax
Puma Biotechnology
Endocyte
Alnylam
Bluebird Bio
Dyax
Medivation
Clovis Oncology
Achillion
Insmed
Arena Pharmaceuticals
Avanir
Receptos
Synergy Pharmaceuticals
ChemoCentryx
Idenix
MiMedx
Portola Pharmaceuticals
Medivation and Astellas Initiate Phase 2 Study of Enzalutamide in Breast Cancer Patients
Yahoo
Wed, 06/26/13 - 10:44 am
Medivation
Astellas
Enzalutamide
breast cancer
Astellas' Xtandi approved in EU for prostate cancer
Pharma Times, UK
Mon, 06/24/13 - 10:50 am
Astellas
Xtandi
prostate cancer
Europe
Medivation
Medivation retreats after J&J beefs up prostate cancer slate
The Fly on the Wall
Mon, 06/17/13 - 12:37 pm
JNJ
M&A
Medivation
prostate cancer
Aragon
Zytiga
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Yahoo/BusinessWire
Fri, 05/24/13 - 10:37 am
Astellas
Medivation
Enzalutamide
prostate

Pages